Morgan Stanley Medicenna Therapeutics Corp. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MDNA
# of Institutions
3Shares Held
863KCall Options Held
0Put Options Held
0About Medicenna Therapeutics Corp.
- Ticker MDNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 69,637,504
- Market Cap $21.6M
- Description
- Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...